Dipyridamole: a possible potent inhibitor of thromboxane A2 synthetase in vascular smooth muscle. 1977

A I Ally, and M S Manku, and D F Horrobin, and R O Morgan, and M Karmazin, and R A Karmali

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D009130 Muscle, Smooth Unstriated and unstriped muscle, one of the muscles of the internal organs, blood vessels, hair follicles, etc. Contractile elements are elongated, usually spindle-shaped cells with centrally located nuclei. Smooth muscle fibers are bound together into sheets or bundles by reticular fibers and frequently elastic nets are also abundant. (From Stedman, 25th ed) Muscle, Involuntary,Smooth Muscle,Involuntary Muscle,Involuntary Muscles,Muscles, Involuntary,Muscles, Smooth,Smooth Muscles
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013928 Thromboxane A2 An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS). Rabbit Aorta Contracting Substance,A2, Thromboxane
D013930 Thromboxane-A Synthase An enzyme found predominantly in platelet microsomes. It catalyzes the conversion of PGG(2) and PGH(2) (prostaglandin endoperoxides) to thromboxane A2. EC 5.3.99.5. Thromboxane Synthetase,Thromboxane A Synthase,Thromboxane A2 Synthetase,A2 Synthetase, Thromboxane,Synthase, Thromboxane A,Synthase, Thromboxane-A,Synthetase, Thromboxane,Synthetase, Thromboxane A2
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

A I Ally, and M S Manku, and D F Horrobin, and R O Morgan, and M Karmazin, and R A Karmali
January 1986, Thrombosis research,
A I Ally, and M S Manku, and D F Horrobin, and R O Morgan, and M Karmazin, and R A Karmali
December 1981, Naunyn-Schmiedeberg's archives of pharmacology,
A I Ally, and M S Manku, and D F Horrobin, and R O Morgan, and M Karmazin, and R A Karmali
November 1995, Hypertension (Dallas, Tex. : 1979),
A I Ally, and M S Manku, and D F Horrobin, and R O Morgan, and M Karmazin, and R A Karmali
April 1993, The Journal of pharmacology and experimental therapeutics,
A I Ally, and M S Manku, and D F Horrobin, and R O Morgan, and M Karmazin, and R A Karmali
September 1977, Prostaglandins,
A I Ally, and M S Manku, and D F Horrobin, and R O Morgan, and M Karmazin, and R A Karmali
November 1996, Nihon rinsho. Japanese journal of clinical medicine,
A I Ally, and M S Manku, and D F Horrobin, and R O Morgan, and M Karmazin, and R A Karmali
January 1997, Agents and actions. Supplements,
A I Ally, and M S Manku, and D F Horrobin, and R O Morgan, and M Karmazin, and R A Karmali
May 1996, The Journal of surgical research,
A I Ally, and M S Manku, and D F Horrobin, and R O Morgan, and M Karmazin, and R A Karmali
January 1987, Federation proceedings,
A I Ally, and M S Manku, and D F Horrobin, and R O Morgan, and M Karmazin, and R A Karmali
June 1999, European journal of pharmacology,
Copied contents to your clipboard!